Hepatitis C
Conditions
Brief summary
The purpose of this study is to estimate the effect of filibuvir on the pharmacokinetics of ethinyloestradiol \[EE\] and levonorgestrel \[LN\], to assess the safety and tolerability of 600 mg BID of filibuvir in healthy women and to investigate the pharmacokinetics of 600 mg BID of filibuvir in healthy women.
Detailed description
To investigate the effects of multiple oral doses of filibuvir on the steady state pharmacokinetics of oral contraceptive steroids in healthy female subjects.
Interventions
DRUGfilibuvir + Oral Contraceptives
This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
Sponsors
Pfizer
Study design
Intervention model
CROSSOVER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy female subjects between the ages of 18 and 45 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). * Subjects must have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1. * Body Mass Index (BMI) of approximately 17.5 to 30.5 kg/m2; and a total body weight \>45 kg. * Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. * Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. * Must be willing to practice an alternative method of contraception for the duration of the study in addition to oral contraceptive use.
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Any medical reason which would contraindicate the administration of oral contraceptives (as per label). Including but not limited to history of unexplained vaginal bleeding, current breast cancer, active liver disease, uncontrolled hypertension, history of diabetes with vascular complications, history of venous thrombosis, stroke, ischemic heart disease, history of severe headaches with focal neurologic symptoms. * Female subjects of non-childbearing potential who meet the following criteria: * Post menopausal, aged between 45-55 who have been amenorrheic for \>2 years and who meet the criteria for serum FSH levels (\>30 IU/L), or * Females who have undergone a hysterectomy, or * Females who have undergone tubal ligation, or * Females who have undergone bilateral oophorectomy. * History of discontinued use of oral contraceptives for medical reasons. * History of febrile illness within 5 days prior to the first dose. * Any condition possibly affecting drug absorption (eg, gastrectomy).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCtau, Cmax, for LN and EE on Day 21 in Period 1 and Period 2. | 21 days |
Secondary
| Measure | Time frame |
|---|---|
| LN and EE - Tmax and t1/2 (if data permit) in Period 1 and Period 2. Filibuvir - AUCtau, Cmax, Cmin, and Tmax on Day 28 of Period 1 and Day 21 of Period 2. | 21 days |
| Safety (AE, lab, vital, ECG, etc). | 21 days |
Countries
Belgium
Outcome results
None listed